Rova-T (rovalpituzumab tesirine) is an investigational antibody drug conjugate targeting the cancer stem cell-associated target delta-like protein 3 (DLL3). It is also being investigated as a combination therapy with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a second-line treatment for extensive-stage small cell lung cancer (SCLC).
Type of Molecule
|Potential Indication||Product Type||Phase (1, 2, 3, Submitted, Approved)|
|Small Cell Lung Cancer (1L SCLC)||New Indication||Phase 3|
|Small Cell Lung Cancer (3L SCLC)||New Indication||Phase 2|
|Neuroendocrine Tumors||New Indication||Phase 1|
|Small Cell Lung Cancer (2L SCLC)||New Indication||Phase 2|